CME Group (CME) reported results in line with expectations in FY2026 on revenue of $148.8B versus the $149.8B estimate (+25.7% YoY) and EPS of $2.29. Below is the full CME Group earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
CME Group (CME) Earnings Analysis — key stats
Next earnings date
Jan 30, 2025
Latest reported quarter
FY2026
Earnings verdict
In line
Revenue
$148.8B (vs $149.8B est · -0.7% surprise · +25.7% YoY)
EPS
$2.29 (vs $2.28 est · +0.4% surprise · +12.1% YoY)
Share price
$598.49 (-3.8%)
Market cap
$750.0B
What you'll find
Next CME Group (CME) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment CME Group reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in CME Group (CME)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is CME Group's next earnings date?
CME Group's (CME) next scheduled earnings date is Jan 30, 2025. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did CME Group (CME) beat or miss earnings?
In FY2026, CME Group (CME) posted in-line results — revenue of $148.8B versus the $149.8B estimate (-0.7% surprise) and EPS of $2.29 versus $2.28 expected (+0.4% surprise). Magnisto decodes every CME Group (CME) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
What is the forecast for CME Group (CME) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for CME Group (CME), anchored to the current $598.49 share price, so you can weigh the bull, base and bear cases for CME Group side by side.
Is CME Group (CME) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether CME Group fits your own thesis and risk profile. This is research, not investment advice.